# A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

> **NCT01468688** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- 3rd Line GIST

## Interventions

- **DRUG:** STI571
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01468688
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-20
- **Primary completion:** 2016-07-29
- **Final completion:** 2016-07-29
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468688, "A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01468688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*